BioSpace News Archive

ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company developing novel therapeutics for global markets, today announced the completion of the first part of the single ascending dose (SAD) study testing the intravenous formulation of the first-in-class therapeutic antibody ASLAN004 in healthy volunteers.

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into UnitedHealth Group Incorporated.

Label Updated to Include Reduction in Exacerbations and Major Adverse Cardiovascular Event Safety Data in Cardiovascular-Risk COPD Patients

imaware™, the at-home testing platform for chronic illness and disease, designed by healthcare company Microdrop, today announced a study utilizing its platform has been peer reviewed by one of the world’s top clinical chemistry journals, Clinical Chemistry and Laboratory Medicine (CCLM).

HypnoVR, developing virtual reality-based medical hypnosis solutions to manage pain and stress, today announces it has concluded three promising retrospective clinical trials for managing pain and anxiety during and after medical procedures.

On March 27, 2019, ThermoLife International, LLC filed suit in Arizona Federal District Court against Olympus Labs. ThermoLife’s Complaint brings claims against Olympus Labs for false advertising under 25 U.S.C. § 1125(d), false marking under 35 U.S.C. § 292 and unfair competition.

Hologic, Inc.’s (Nasdaq: HOLX) Cynosure division announced today it will partner with key opinion leaders to present 19 scientific abstracts on its industry-leading medical aesthetics technology at the 39th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS).

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved MAVENCLAD® (cladribine) tablets for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS)

SkinBioTherapeutics plc (AIM: SBTX or the “Company”), a life sciences company focused on skin health, announces the appointment of Stuart Ashman as an Executive Director of the Company, subject to the completion of regulatory due diligence checks.

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III study comparing surufatinib (HMPL-012 or sulfatinib) with capecitabine in patients with advanced biliary tract cancer (“BTC”) whose disease progressed on first-line chemotherapy.